Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Sernova Corp
T.SVA
Alternate Symbol(s):
SEOVF
Healthcare
Biotechnology
Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch...
System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:SVA)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(121)
•••
BioTeck
X
View Profile
View Bullboard History
Post by
BioTeck
on Jan 18, 2023 11:59am
Time to cool it.
Wellllll, that was a solid return on investment. All those shares bought in the 70's have officially been disposed of. I think the price will cool off as Sernova likely won't put out any news
...more
(57)
•••
Iseneschal
X
View Profile
View Bullboard History
Comment by
Iseneschal
on Jan 17, 2023 1:20pm
RE:SVA .... On watch
I always say .... Price is King Price action says....this is heading higher Cheers !
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA
posted Apr 25, 2024 9:00am by
Indiva Ltd
-
|
“Net Income was just shy of break-even in Q4, which is a testament to the popularity of our products, our industry leading low-cost production platform, and our focus on cost control. Our core brands, namely Pearls by Grön, No Future, Bhang Chocolate and Indiva Blips continue to gain market share in Canada, as Indiva continues to hold the #1 market share position in edibles nationally," said ...read more
(121)
•••
BioTeck
X
View Profile
View Bullboard History
Comment by
BioTeck
on Jan 16, 2023 6:57pm
RE:RE:RE:RE:RE:VCTX210
You are mistaken unless you're talking about preclinical results. That is still a pie in the sky dream for vertex as it is for sernova.
(12)
•••
Ekenbullets
X
View Profile
View Bullboard History
Comment by
Ekenbullets
on Jan 16, 2023 5:37pm
RE:RE:RE:RE:VCTX210
Vctx210 is with crispr and phase 1 clinical, should have ended in dec. Waiting for some results.
(121)
•••
BioTeck
X
View Profile
View Bullboard History
Comment by
BioTeck
on Jan 16, 2023 4:17pm
RE:RE:RE:VCTX210
The immuno suppression is being done at a macro level on the device. My guess is that it won't work out very well, if at all. Viacyte likely knew this too and probably sold themselves to
...more
(12)
•••
Ekenbullets
X
View Profile
View Bullboard History
Comment by
Ekenbullets
on Jan 16, 2023 4:08pm
RE:RE:VCTX210
Thanks, I know about the study what Im interested in is any output from it. Think it ended december.
(121)
•••
BioTeck
X
View Profile
View Bullboard History
Comment by
BioTeck
on Jan 16, 2023 1:28pm
RE:VCTX210
https://www.globenewswire.com/news-release/2022/02/02/2377646/0/en/CRISPR-Therapeutics-and-ViaCyte-Inc-Announce-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-Novel-Gene-Edited-Cell-Replacement
...more
(12)
•••
Ekenbullets
X
View Profile
View Bullboard History
Post by
Ekenbullets
on Jan 16, 2023 12:24pm
VCTX210
Anyone heard anything about an update of VCTX210 which where to end in dec?
(3)
•••
stockhunter1
X
View Profile
View Bullboard History
Post by
stockhunter1
on Jan 16, 2023 10:21am
NEW!! SIX buck target. Link to the report
If you could not find the report from H.C Wainwright...enjoy this, it is well written! https://cdn-ceo-ca.s3.amazonaws.com/1hrrmed-HCWupdate.pdf
(121)
•••
BioTeck
X
View Profile
View Bullboard History
Comment by
BioTeck
on Jan 16, 2023 9:28am
RE:RE:NEW!! SIX buck target.
Thanks Merc. I did tell everyone to buy while you can.
(21)
•••
Mercuryfilling1
X
View Profile
View Bullboard History
Comment by
Mercuryfilling1
on Jan 16, 2023 7:54am
RE:NEW!! SIX buck target.
Well, between Dougie LowBall Loe's prediction, the waning-right's $6 optimism, and Phil's uncontrolled smirking, I figure something's up. Only question is, who are they planning to
...more
(3)
•••
stockhunter1
X
View Profile
View Bullboard History
Post by
stockhunter1
on Jan 14, 2023 11:36am
NEW!! SIX buck target.
January 10-2023 Joseph Pantginis from H.C. Wainwright & Co. has done a fine job writing an analysis on Sernova. He is both a Ph.D and an M.S in Molecular Genetics and as such his evaluation was
...more
(115)
•••
rixpix
X
View Profile
View Bullboard History
Comment by
rixpix
on Jan 13, 2023 2:04pm
RE:RE:SVA .... On watch
LMAO!!! :))))
(121)
•••
BioTeck
X
View Profile
View Bullboard History
Comment by
BioTeck
on Jan 13, 2023 10:37am
RE:SVA .... On watch
Keep watching...
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Stage Set for Creation of a Leading Intermediate Gold Producer
Centurion Identifies High Quality Gold Target-Casa Berardi West Project; Acquires Additional Claims
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study
Discover a Green Resources Stock Scoring Record Quarterly Growth
Two New Contracts Awarded Covering Five Onshore Fields Producing 3,000 bbl/d of Oil